Home > Insider Trading > Filing (0001209191-17-035176)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1560241	G1 Therapeutics Inc.	GTHX	Pharmaceutical Preparations (2834)	263648180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1706673	Eshelman Ventures, Llc	C/O G1 Therapeutics, Inc. 79 T.w. Alexander Drive Research Triangle Park NC 27709		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-05-22	3,139,151	$0.00	3,139,151	No	4	C	Direct
Common Stock	Acquisiton	2017-05-22	300,000	$15.00	3,439,151	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2017-05-22	6,893,224	$0.00	2,297,740	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-05-22	2,524,233	$0.00	841,411	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and the Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.
Dr. Fredric Eshelman is the founder and principal of Eshelman Ventures, LLC and may be deemed to beneficially own the securities held by Eshelman Ventures, LLC. Dr. Eshelman disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Reflects shares Eshelman Ventures, LLC purchased in the initial public offering at the initial public offering price of $15.00 per share.
The Series B Preferred Stock and the Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.